Glaxosmithkline Pharmaceuticals Ltd Quarterly Results

Gross Sales

979.94

805.17

974.37

949.42

1,010.77

Excise Duty

0

0

0

0

0

Net Sales

979.94

805.17

974.37

949.42

1,010.77

Other Operating Income

0

0

0

0

0

Other Income

36.21

43.72

40.68

35.07

39.23

Total Income

1,016.15

848.89

1,015.05

984.49

1,050

Total Expenditure

644.21

553.97

641.18

657.5

689.06

PBIDT

371.94

294.92

373.87

326.99

360.94

Interest

0.51

0.42

0.58

0.09

0.27

PBDT

371.43

294.5

373.29

326.9

360.67

Depreciation

17.43

15.52

14.72

18.8

16.86

Minority Interest Before NP

0

0

0

0

0

Tax

96.07

73.95

90.15

73.49

98.76

Deferred Tax

0.44

0.02

5.55

4.73

-7.45

Reported Profit After Tax

257.49

205.01

262.87

229.88

252.5

Minority Interest After NP

0

0

0

0

0

Net Profit after Minority Interest

257.49

205.01

262.87

229.88

252.5

Extra-ordinary Items

1.92

0

0

0

3.34

Adjusted Profit After Extra-ordinary item

255.57

205.01

262.87

229.88

249.16

EPS (Unit Curr.)

15.07

12.1

15.52

13.57

14.67

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

0

0

0

240

120

Equity

169.41

169.41

169.41

169.41

169.41

Public Shareholding (Number)

0

0

0

0

0

Public Shareholding (%)

0

0

0

0

0

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

0

0

0

0

0

Non Encumbered - % in Total Promoters Holding

0

0

0

0

0

Non Encumbered - % in Total Equity

0

0

0

0

0

PBIDTM(%)

37.95

36.62

38.37

34.44

35.7

PBDTM(%)

37.9

36.57

38.31

34.43

35.68

PATM(%)

26.27

25.46

26.97

24.21

24.98